- Home
- ENLV vs SLGL Comparison
ENLV vs SLGL Comparison
Compare ENLV & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENLV | SLGL |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.7M | 247.1M |
| IPO Year | 2014 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ENLV | SLGL |
|---|---|---|
| Price | $0.82 | $76.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $20.00 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 756.6K | 44.6K |
| Earning Date | 05-29-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.42 |
| 52 Week High | $2.10 | $97.97 |
Technical Indicators
Market Signals| Indicator | ENLV | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 37.33 | 50.26 |
| Support Level | $0.81 | $71.01 |
| Resistance Level | $1.19 | $95.83 |
| Average True Range (ATR) | 0.11 | 7.12 |
| MACD | -0.01 | -0.25 |
| Stochastic Oscillator | 13.06 | 58.90 |
Price Performance
Historical ComparisonAbout ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.